当基于价值合同下的归因生命计划未执行时，通常原因是提供者理性优化合同实际奖励的每例成本和支付方组合。 对医疗机构而言，难点在于结构性问题：已在38,000个生命上接受下行风险，却缺乏定价所需每例成本数据。任何可信答案都必须同时持有每例成本和支付方组合，而这正是大多数内部分析停滞之处，因为两者分属不同系统。
当基于价值合同下的归因生命计划未执行时，通常原因是提供者理性优化合同实际奖励的每例成本和支付方组合。 对医疗机构而言，难点在于结构性问题：已在38,000个生命上接受下行风险，却缺乏定价所需每例成本数据。任何可信答案都必须同时持有每例成本和支付方组合，而这正是大多数内部分析停滞之处，因为两者分属不同系统。
执行失败很少源于不愿执行。通常是计划要求的行为与现有每例成本追踪、支付方组合目标和面板规模激励相冲突，于是提供者按贡献每提供者指标所支付的方式解决冲突。
诊断问题不是为什么没人遵循基于价值的合同，而是提供者在面板规模或贡献每提供者上被要求放弃什么，以及谁来补偿他们。一项要求团队在缺乏每例成本数据的情况下接受归因生命下行风险的计划不会运行。
第二个常见原因是算术：计划需要不存在的每例成本可见性，组织并未明说，而是悄悄只管理能测量的归因生命子集，其余基于价值的合同部分从未发生。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 基于价值的合同条款已为医务主任和首席财务官理解，但每例成本仍保持不变
✓ 进展在报告中显示为归因生命 enrollment 数量，而非每例成本变化
✓ 被要求改变的提供者仍按面板规模和贡献每提供者考核
通常会让情况更糟的做法。 更努力传达基于价值的合同，这解决的是不存在的理解问题，并延误寻找实际需要的每例成本数据和激励调整。
It is for you if you run or finance a healthcare provider and the plan is understood and agreed and still nothing changes. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗机构. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Convert existing downside-risk scale into CMS-mandated quality infrastructure that locks in 48+ month structural durability.
The leak it closes. Binary default risk on $6.8M revenue eliminated through cost-per-episode analytics
The assumption it rests on. CMS continues ACO REACH program through 2030 — the engine put the probability at 0.85.
| Investment required | $225-325K total over 36 months ($75K regulatory consultant + $150-250K analytics tooling) |
| Expected return | 69.8× on $325K investment if ACO REACH approved — derived from $22.7M NPV upside / $325K investment |
| Revenue, year 1 | $0 incremental (application phase) |
| Revenue, year 2 | $1.0M incremental (0.5 point margin lift on $196M) |
| Revenue, year 3 | $2.0M incremental (1.0 point margin lift on $196M) |
| Exit criteria | Abandon if CMS terminates ACO REACH program OR physician ownership falls below 55% OR application rejected after two submissions |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 组织对齐模型, one of 29 engagements the platform runs. For 医疗机构 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
在要求人们改变行为前，先改变对他们的考核指标。认同更可靠地跟随激励，而非解释。
偶尔是。更常见的是结构问题伪装成人员问题，先测试这一点值得，因为更换人员无法修复结构，且发现成本高昂。
通常应该，但出于容量而非理解原因。三项符合可用容量的优先事项胜过十二项不符合的计划。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית